PL434248A1 - Staphylococcus aureus strain for the production of monoclonal phage preparations deprived of impurities by plasmid DNA - Google Patents
Staphylococcus aureus strain for the production of monoclonal phage preparations deprived of impurities by plasmid DNAInfo
- Publication number
- PL434248A1 PL434248A1 PL434248A PL43424814A PL434248A1 PL 434248 A1 PL434248 A1 PL 434248A1 PL 434248 A PL434248 A PL 434248A PL 43424814 A PL43424814 A PL 43424814A PL 434248 A1 PL434248 A1 PL 434248A1
- Authority
- PL
- Poland
- Prior art keywords
- production
- plasmid dna
- staphylococcus aureus
- deprived
- impurities
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00051—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Ujawniono szczep Staphylococcus aureus do otrzymywania monoklonalnych preparatów bakteriofagów litycznych o wysokim mianie, pozbawionych zanieczyszczeń niepożądanymi bakteriofagami oraz plazmidowym DNA, który gwarantuje produkcję bezpiecznych w stosowaniu preparatów bakteriofagowych nie będących źródłem rozsiewu genów związanych z wirulencją bakterii.The Staphylococcus aureus strain was disclosed for the production of monoclonal preparations of lytic bacteriophages with high titer, free from contamination with unwanted bacteriophages and plasmid DNA, which guarantees the production of safe to use bacteriophage preparations that are not a source of genes related to bacterial virulence.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL434248A PL236569B1 (en) | 2014-08-31 | 2014-08-31 | Staphylococcus aureus strain for the production of monoclonal phage preparations deprived of impurities by plasmid DNA |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL434248A PL236569B1 (en) | 2014-08-31 | 2014-08-31 | Staphylococcus aureus strain for the production of monoclonal phage preparations deprived of impurities by plasmid DNA |
Publications (2)
Publication Number | Publication Date |
---|---|
PL434248A1 true PL434248A1 (en) | 2020-10-05 |
PL236569B1 PL236569B1 (en) | 2021-01-25 |
Family
ID=72669373
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL434248A PL236569B1 (en) | 2014-08-31 | 2014-08-31 | Staphylococcus aureus strain for the production of monoclonal phage preparations deprived of impurities by plasmid DNA |
Country Status (1)
Country | Link |
---|---|
PL (1) | PL236569B1 (en) |
-
2014
- 2014-08-31 PL PL434248A patent/PL236569B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
PL236569B1 (en) | 2021-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20200192A1 (en) | Anti-tigit antibodies | |
PH12016502555A1 (en) | Methods of preparing substituted nucleotide analogs | |
DK3400290T3 (en) | Oncolytic virus strain | |
PH12017500858A1 (en) | Mocrocyclic peptides useful as immunomodulators | |
IL262762A (en) | Methods for diagnosis of bacterial and viral infections | |
WO2015153889A3 (en) | Materials and methods for the treatment of latent viral infection | |
DK3377082T3 (en) | COMPOSITIONS INCLUDING BACTERIA STRAINS | |
MX2017008184A (en) | Substituted nucleosides, nucleotides and analogs thereof. | |
EA201891202A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
EA201891201A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
EA201890050A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
EA201890049A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
BR112017024123A2 (en) | expression constructs and genetic engineering manipulation methods of methylilotrophic yeast | |
MX2017006652A (en) | Aav vectors targeted to the central nervous system. | |
EA201691534A1 (en) | TREATMENT OF SUSTAINABLE UGRAI | |
EA201790265A1 (en) | METHODS FOR OBTAINING PLATELET-CONTAINING PRODUCTS | |
MX2017015462A (en) | Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases. | |
EP3324987A4 (en) | Bacteriophage for treating staphylococcus infections | |
SI3400225T1 (en) | Pentanoic acids substituted by pyrrolo-(2-3,b)pyrimidine-pyridines for the treatment of influenza viral infections | |
MX2020013096A (en) | Semisynthetic routes to organic compounds. | |
CL2017000151A1 (en) | Pyridone derivatives | |
MX2018005872A (en) | Nucleic acid prodrugs. | |
PL409332A1 (en) | Enterococcus faecalis strains for the production of monoclonal phage preparations | |
PL409330A1 (en) | Staphylococcus aureus strains for the production of monoclonal phage preparations deprived of impurities by plasmid DNA | |
PL434248A1 (en) | Staphylococcus aureus strain for the production of monoclonal phage preparations deprived of impurities by plasmid DNA |